Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646223
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratoriesNot Yet RecruitingPhase 2
NCT07646223Not Yet Recruiting
Phase 2
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratories
NCT07644208
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative HepatectomyShanghai Zhongshan HospitalNot Yet RecruitingPhase 2
NCT07644208Not Yet Recruiting
Phase 2
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatoc...Shanghai Zhongshan Hospit...
NCT07645859
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuous Training in Chronic Non-Specific Low Back Pain PatientsDow University of Health SciencesRecruitingNot Applicable
NCT07645859Recruiting
Not Applicable
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuou...Dow University of Health...
NCT07643974
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research InstituteNot Yet RecruitingEarly Phase 1
NCT07643974Not Yet Recruiting
Early Phase 1
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research I...
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07645183
Advanced Technology for Myopia Control in Children and Young AdultsUniversity of FaisalabadCompletedNot Applicable
NCT07645183Completed
Not Applicable
Advanced Technology for Myopia Control in Children and Young AdultsUniversity of Faisalabad
NCT07644169
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG) in Healthy Adults Following PG ExposureAmerican Beverage AssociationNot Yet RecruitingNot Applicable
NCT07644169Not Yet Recruiting
Not Applicable
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG)...American Beverage Associa...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07645118
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerDr. Te VuongNot Yet RecruitingPhase 2
NCT07645118Not Yet Recruiting
Phase 2
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerDr. Te Vuong
NCT07645274
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)Indiana UniversityNot Yet RecruitingNot Applicable
NCT07645274Not Yet Recruiting
Not Applicable
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led...Indiana University
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07646483
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee OsteoarthritisPharmaResearch Co.,LtdNot Yet RecruitingNot Applicable
NCT07646483Not Yet Recruiting
Not Applicable
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and...PharmaResearch Co.,Ltd
NCT07645404
The Effect of Mental Fatigue on Upper Extremity Functional PerformanceIzmir Bakircay UniversityNot Yet RecruitingNot Applicable
NCT07645404Not Yet Recruiting
Not Applicable
The Effect of Mental Fatigue on Upper Extremity Functional PerformanceIzmir Bakircay University
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644923
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated CoagulationNYU Langone HealthNot Yet RecruitingPhase 4
NCT07644923Not Yet Recruiting
Phase 4
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled Wit...NYU Langone Health
NCT07643909
Health-Related Social Needs Food Boxes Delivery ProgramBoston Medical CenterNot Yet RecruitingNot Applicable
NCT07643909Not Yet Recruiting
Not Applicable
Health-Related Social Needs Food Boxes Delivery ProgramBoston Medical Center
NCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic CancerCarrick Therapeutics LimitedNot Yet RecruitingPhase 1
NCT07645651Not Yet Recruiting
Phase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectabl...Carrick Therapeutics Limi...
Result Breakdown
Not yet recruiting15 (75%)
Recruiting4 (20%)
Completed1 (5%)
not_applicable8 (40%)
Phase 25 (25%)
Phase 42 (10%)
Phase 12 (10%)
Early Phase 11 (5%)
Not Specified1 (5%)
Phase 31 (5%)